Our client Uvence has developed a revolutionary manufacturing and logistics platform to supply all cosmetic doctors in the UK with injectable regenerative skin treatments. These harness the power of our own naturally occurring regenerative tissues providing powerful outcomes without the use of synthetic chemicals, fillers or neurotoxins. Prior to Uvence these natural regenerative treatments were restricted to a small number of surgeons, who provide a bespoke surgical service. Uvence has standardised and productised this cutting-edge, high margin treatment, creating a simple on-demand delivery platform that increases the addressable market by >50x.
The company is based in London and are seeking two or three investing Non-Executive Directors with the following areas of expertise:
- Sales and Marketing experience: connected within the B2B Medical sales sector, particularly in cosmetic injectables or consumables, with a well-developed network.
- Experience of Cosmetic Medicine / Clinic / Premium Beauty and Logistics/Supply Chain and scaling thereof.
- Experience of International licensing / franchising.
- We are seeking an additional Non Exec with financial expertise to become the Non Exec FD.
All candidates are likely to have business strategy / growth experience and to have been involved in fast growing early-stage businesses or divisions.
It is expected that the role will require approximately 2 or 3 days per month – potentially more in the early stages.
The incoming Non-Executive Directors will be required to become shareholders in the Company with an initial investment of a minimum of £50k to align their interests with those of the existing Board Members.
Market & Opportunity:
- The medical injectables market is c. $7bn annually and growing at a double-digit rate.
- Existing products include Botox, Hyaluronic Acid fillers and PRP (derived from blood plasma). It is estimated that almost a million procedures are performed annually in the UK and such treatments have become comparable to a haircut or manicure.
- McKinsey research shows that the global aesthetics injectables market could grow by 12 to 14 percent a year over the next five years.
- Over the last ten years the medicine, health and wellness industries have converged on some new thinking. This is the awareness of and focus on the use of natural, holistic and highly personalised products and treatments that optimise/harness our body's innate self-repair mechanisms to maintain health, youth and vigour. This embraces nutrition, "biohacking", the microbiome and ways to stimulate or engineer our own immune system (such as immunotherapy).
- The evolution of injectable beauty treatments derived from our own bodies is at the leading edge of this trend but although the basic science is 30 years old the supply chain and accessibility of products is in its infancy. Accordingly, despite the demonstrated efficacy of such treatments they only accessible to a few hundred surgeons and their clients.
- Uvence was created to solve this problem for cosmetic doctors and their patients by providing a common B2B industry platform that supplies standardised, quality controlled injectables to cosmetic doctors using tissues harvested from their patients. At scale this opens up the market by more than 50x in the UK and an order of magnitude beyond.
- Founded in 2019, Uvence launched a pilot study in patients in 2020. Based on the success of that program the team raised capital to industrialise the process, establish a manufacturing capacity and gain regulatory approval. At present the business is poised for full commercial launch in Q1 2024 in partnership with the Cadogan Clinic and is seeking investor/NED's with appropriate experience in medical sales, logistics, supply chain and medical injectables.
The incoming Non-Executive Directors will be encouraged to become shareholders in the Company with an initial investment of £50k to align their interests with that of the existing Board Members. A copy of the pitch deck will be provided to candidates who meet the criteria and on signing an NDA.
The company is registered for EIS & SEIS tax relief.
No Remuneration will be paid to the incoming Non Execs until the company is cash positive and profitable which is expected to be within 18 months.
Applying for the role:
Candidates who feel they meet the above criteria are invited to apply having first registered their CV with First Flight Non-Executive Directors (if they have not already done so – there is no charge) by using our “Apply for Role” tab for role no: 1205 and completing the application form explaining how they match the key criteria we have set out for the role.
Closing date for applications: 19th February 2024
